- Home
- DYAI vs BOLD Comparison
DYAI vs BOLD Comparison
Compare DYAI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DYAI | BOLD |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 28.0M |
| IPO Year | 2004 | 2024 |
Fundamental Metrics
Financial Performance| Metric | DYAI | BOLD |
|---|---|---|
| Price | $0.88 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $4.00 |
| AVG Volume (30 Days) | 77.9K | ★ 118.6K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,342,195.00 | N/A |
| Revenue This Year | $12.52 | N/A |
| Revenue Next Year | $92.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $1.00 |
| 52 Week High | $1.79 | $2.77 |
Technical Indicators
Market Signals| Indicator | DYAI | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 54.14 |
| Support Level | $0.85 | $1.21 |
| Resistance Level | $0.93 | $1.35 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 31.87 | 52.38 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.